SAPIEN 3 – Medxy AI

Decade-Long Outcomes of SAPIEN 3 TAVR vs. Surgery in Intermediate-Risk Aortic Stenosis Patients

By MedXY 06/20/2026

This analysis reveals comparable 10-year mortality, valve durability, and hemodynamics between SAPIEN 3 transcatheter and surgical aortic valve replacement in intermediate-risk patients, underscoring TAVR's durable benefit.

Cardiology news

Sustainable Hemodynamic Recovery in Large RVOTs: 3-Year Outcomes of the Alterra Adaptive Prestent and SAPIEN 3 THV

By MedXY 03/02/2026

Three-year pooled data from the ALTERRA trials demonstrate that the Alterra Adaptive Prestent combined with the SAPIEN 3 THV is highly effective and safe for treating severe pulmonary regurgitation in patients with large right ventricular outflow tracts, showing sustained durability and low reintervention rates.

Cardiology Clinical Updates news Specialties

Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial

By MedXY 09/07/2025

The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.